Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $28.42, but opened at $30.33. Collegium Pharmaceutical shares last traded at $31.22, with a volume of 40,596 shares changing hands.
The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%.
Analyst Upgrades and Downgrades
COLL has been the topic of a number of recent analyst reports. Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target on the stock in a research report on Friday, January 10th. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, Piper Sandler reduced their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.60.
Check Out Our Latest Stock Report on Collegium Pharmaceutical
Insider Activity at Collegium Pharmaceutical
In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company's stock, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.98% of the stock is owned by company insiders.
Institutional Investors Weigh In On Collegium Pharmaceutical
Several large investors have recently modified their holdings of COLL. Invesco Ltd. grew its holdings in Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after purchasing an additional 289,335 shares during the period. Janus Henderson Group PLC lifted its position in shares of Collegium Pharmaceutical by 319.4% during the 4th quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock valued at $8,341,000 after buying an additional 221,903 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company's stock worth $27,461,000 after acquiring an additional 215,874 shares during the period. JPMorgan Chase & Co. increased its holdings in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $3,489,000.
Collegium Pharmaceutical Stock Performance
The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market capitalization of $904.29 million, a PE ratio of 12.09 and a beta of 0.82. The company's fifty day simple moving average is $30.81 and its 200 day simple moving average is $33.39.
Collegium Pharmaceutical Company Profile
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Articles
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
